Reply to: “Sorafenib or 90Y loaded resin microsphere radioembolization for locally‐advanced hepatocellular carcinoma, what should we trust?”

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|35|6|1780-1781

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.35, Iss.6, 2015-06, pp. : 1780-1781

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sorafenib‐ or 90Y‐loaded resin microsphere radioembolization for locally advanced hepatocellular carcinoma, what should we trust?

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 6, 2015-06 ,pp. : 1779-1780

John Wiley & Sons Inc

Access to resources Recommend Favorite

Yttrium‐90 radioembolization vs sorafenib for intermediate‐locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 3, 2015-03 ,pp. : 1036-1047

John Wiley & Sons Inc

Access to resources Recommend Favorite

Yttrium-90 Radioembolization for Hepatocellular Carcinoma: What We Know and What We Need to Know

By  

Oncology, Vol. 84, Iss. 1, 2013-02 ,pp. : 34-39

Karger

Access to resources Recommend Favorite

Education and Imaging

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 3, 2015-03 ,pp. : 438-438

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 2, 2015-02 ,pp. : 620-626

John Wiley & Sons Inc

Access to resources Recommend Favorite